FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?
Executive Summary
FDA will look at which should come first – benefits or risks – when it studies patients' response to three one-page prototypes of patient medication information.
You may also be interested in...
One-Page Patient Medication Information Document Moves Forward Under Proposed Rule
After decades of work, the US FDA released proposed requirements for a simplified version of the Medication Guide for all products. Electronic distribution in lieu of paper ‘upon a patient’s request’ would be allowed. Comments sought on the value of consumer testing of the documents.
FDA “Reminds” Doctors To Talk About Drug Benefits
Proposed pilot program would look for the best patient counseling practices, but can FDA remind providers to discuss a drug’s benefits without actually specifying them?
Whose Burden Is It Anyway? REMS’ Health Care Impact Belongs To FDA, PhRMA Says
Industry group contends that FDA should assess whether a REMS places an undue burden on the health care industry – because asking companies to do that evaluation would be an additional burden on the health care system.